India’s first Zika vaccine has moved closer to human clinical trials after a CDSCO expert panel recommended Phase I testing, marking an important milestone in vaccine development.
India has taken an important step towards developing its first vaccine against the Zika virus. An expert committee under the Central Drugs Standard Control Organisation (CDSCO) has recommended that Indian Immunologicals Limited (IIL) receive permission to conduct Phase I clinical trials of its Zika vaccine.
The vaccine is being developed through a collaboration between IIL and Australia's Griffith University. The recommendation marks progress in India's efforts to strengthen its preparedness against mosquito-borne viral infections.
According to the minutes of the Subject Expert Committee (SEC) meeting held on November 12, the recommendation was made to the Human Biologicals Institute (HBI), the human healthcare division of IIL.
The proposed vaccine is a recombinant live attenuated Zika vaccine available in freeze-dried form. It is designed to stimulate the body's immune system against the Zika virus.
Zika is primarily transmitted through the bites of infected Aedes mosquitoes. According to UNICEF, no approved vaccine is currently available to prevent the disease.
The development of an indigenous vaccine could strengthen India's ability to address future Zika outbreaks and reduce the potential health risks associated with the infection.
The CDSCO Subject Expert Committee on vaccines recommended proceeding towards Phase I clinical trials after reviewing additional scientific information submitted by HBI.
The proposed clinical study will evaluate the vaccine's:
Safety: To determine whether the vaccine can be administered safely to participants.
Reactogenicity: To assess the short-term reactions and side effects following vaccination.
Immunogenicity: To examine the immune response generated by the vaccine.
The trial protocol proposes a randomised, double-blind and placebo-controlled study involving healthy adults aged between 18 and 50 years.
The recommendation is an important regulatory development. However, it does not mean that human trials have already started. Their commencement will depend on the required regulatory permission and other trial-related arrangements.
HBI had initially submitted its Phase I clinical trial protocol to the expert committee in September 2026. However, the panel requested further scientific and technical information before reconsidering the proposal.
Although the company had completed acute-dose and repeat-dose toxicity studies, along with animal immunogenicity and challenge studies, certain details were missing from its submission.
The committee specifically sought clarification on:
The scientific justification for selecting the vaccine dose for human trials.
Statistical reasoning behind the proposed number of participants.
The justification for adopting a 3:1 randomisation ratio.
The selection of participant groups based on non-clinical study findings.
Complete reports of non-clinical studies instead of summary documents.
During its September 23 meeting, the committee asked the company to provide these details for further examination.
At its November 12 meeting, the SEC reviewed HBI's revised submission, which included the scientific rationale for dose selection and complete non-clinical study reports.
The documents covered single-dose and repeat-dose toxicity assessments, along with immunogenicity findings.
After examining the additional information, the committee recommended that the company be allowed to proceed towards Phase I clinical trials.
This development highlights the importance of detailed safety assessments and scientific evidence before an experimental vaccine can be tested in humans.
The Zika vaccine development programme is also supported by the Indian Council of Medical Research (ICMR).
Around two years ago, IIL signed a memorandum of agreement (MoA) with ICMR to develop India's first recombinant live attenuated vaccine against Zika.
Under the agreement, ICMR will cover the expenses associated with Phase I clinical trials, including:
Clinical trial operations and implementation.
Investigations and medical assessments.
Trial monitoring and related activities.
The clinical trials are planned to be conducted at ICMR's network sites across India.
This partnership brings together government-backed research support and pharmaceutical development expertise to advance the country's vaccine research capabilities.
Zika infection generally causes mild symptoms, and many infected individuals do not require specific medical treatment. However, the virus can pose serious health risks, particularly during pregnancy.
Infection during pregnancy can affect foetal development and potentially lead to microcephaly, a condition in which babies are born with unusually small heads, along with other congenital abnormalities.
Zika infection has also been associated with Guillain-Barré syndrome (GBS), a neurological condition in which the immune system attacks peripheral nerves.
These complications make the development of preventive measures, including vaccines, particularly important.
India recorded its first confirmed Zika virus cases in 2016 and has experienced sporadic, localised outbreaks since then.
Although the reported outbreaks have remained limited to specific locations, the potential consequences of infection continue to be a public health concern.
According to the available information, India has not reported confirmed cases of Zika-associated microcephaly or Guillain-Barré syndrome to date.
The development of an indigenous Zika vaccine could become an important addition to India's public health preparedness, particularly in managing future outbreaks.
Conclusion
India's first Zika vaccine has reached an important development milestone with the CDSCO expert panel recommending Phase I clinical trials. Developed by Indian Immunologicals Limited in collaboration with Griffith University, the vaccine will undergo further evaluation to establish its safety and immune response in humans. The initiative, supported by ICMR, could strengthen India's future preparedness against Zika virus infections.